Top Markets
Coin of the day
Caladrius Biosciences, Inc. Caladrius Biosciences, Inc.

Caladrius Biosciences, Inc.

CLBS
Classement en actions #33300
Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical... Caladrius Biosciences, Inc. operates as a clinical-stage biopharmaceutical company primarily engaged in the development and commercialization of cellular therapies. These therapies aim to either reverse various diseases or stimulate the regeneration of compromised tissue. The company's pipeline includes several key investigational therapies: HONEDRA, which has received the prestigious SAKIGAKE designation, is undergoing Phase II clinical trials as a potential treatment for critical limb ischemia; XOWNA is currently in Phase IIb trials targeting coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy, is being evaluated for chronic kidney disease in patients prior to requiring dialysis. Previously known as NeoStem, Inc., the firm adopted its current name, Caladrius Biosciences, Inc., in June 2015. Established in 1980, the company maintains its corporate headquarters in Basking Ridge, New Jersey.
Prix de l'action
$0.4264
Dernière synchronisation: 2022-09-14
Capitalisation boursière
$7.93M
Changement (1 jour)
-16.44%
Changement (1 an)
0.00%
Pays
US
Échange Caladrius Biosciences, Inc. (CLBS)

Catégorie

Historique du rendement du dividende pour Caladrius Biosciences, Inc. (CLBS)
Le rendement du dividende (TTM) de Caladrius Biosciences, Inc. (symbole boursier : CLBS) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Caladrius Biosciences, Inc. (CLBS) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
CH
0.00%
KR
0.48%
BE